Subtopic Deep Dive
Antioxidant Renoprotective Strategies Cisplatin
Research Guide
What is Antioxidant Renoprotective Strategies Cisplatin?
Antioxidant renoprotective strategies for cisplatin involve antioxidants like N-acetylcysteine, amifostine, and NRF2 inducers to mitigate cisplatin-induced nephrotoxicity through reducing oxidative stress in renal cells.
Clinical and preclinical studies test N-acetylcysteine, amifostine, and novel NRF2 activators to protect kidneys during cisplatin chemotherapy. Dose-timing and biomarkers optimize these protocols. Over 10 key papers since 2012 document mechanisms and interventions, with Özkök and Edelstein (2014) cited 678 times.
Why It Matters
Antioxidant strategies enable higher cisplatin doses for better cancer control in ovarian, head/neck, and testicular tumors while preventing acute kidney injury (AKI) in 20-30% of patients (Özkök and Edelstein, 2014; Peres and Cunha Júnior, 2013). Natural products like cannabidiol reduce oxidative/nitrosative stress and inflammation (Pan et al., 2008). Exosome therapies from mesenchymal stem cells counter renal oxidative stress and apoptosis (Zhou et al., 2013), supporting dose-intensified regimens.
Key Research Challenges
Balancing renoprotection and tumor efficacy
Antioxidants may protect cancer cells alongside kidneys, reducing cisplatin's anticancer effect (Volarević et al., 2019). Interventions must selectively target renal oxidative stress without compromising tumor toxicity. Over 400 citations highlight this knife-edge balance.
Identifying reliable nephrotoxicity biomarkers
No validated biomarkers predict cisplatin AKI onset despite extensive study (Holditch et al., 2019). Biomarkers must guide antioxidant dosing timing. 345 citations underscore gaps in clinical translation.
Translating natural products clinically
Natural antioxidants show preclinical promise but face bioavailability and standardization issues (Fang et al., 2021). Clinical trials lag due to inconsistent dosing. 340 citations review these hurdles.
Essential Papers
Pathophysiology of Cisplatin-Induced Acute Kidney Injury
Abdullah Özkök, Charles L. Edelstein · 2014 · BioMed Research International · 678 citations
Cisplatin and other platinum derivatives are the most widely used chemotherapeutic agents to treat solid tumors including ovarian, head and neck, and testicular germ cell tumors. A known complicati...
Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro
Ying Zhou, Huitao Xu, Wenrong Xu et al. · 2013 · Stem Cell Research & Therapy · 660 citations
Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity
Vladislav Volarević, Bojana Djokovic, Marina Gazdic et al. · 2019 · Journal of Biomedical Science · 405 citations
Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury
Sara J. Holditch, Carolyn Nicole Brown, Andrew M. Lombardi et al. · 2019 · International Journal of Molecular Sciences · 345 citations
Cisplatin is a widely used chemotherapeutic agent used to treat solid tumours, such as ovarian, head and neck, and testicular germ cell. A known complication of cisplatin administration is acute ki...
Natural products: potential treatments for cisplatin-induced nephrotoxicity
Chunyan Fang, Dayong Lou, Liqin Zhou et al. · 2021 · Acta Pharmacologica Sinica · 340 citations
Abstract Cisplatin is a clinically advanced and highly effective anticancer drug used in the treatment of a wide variety of malignancies, such as head and neck, lung, testis, ovary, breast cancer, ...
Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations
Kristen Renee McSweeney, Laura Kate Gadanec, Tawar Qaradakhi et al. · 2021 · Cancers · 320 citations
Administration of the chemotherapeutic agent cisplatin leads to acute kidney injury (AKI). Cisplatin-induced AKI (CIAKI) has a complex pathophysiological map, which has been linked to cellular upta...
Mechanism of Cisplatin-Induced Cytotoxicity Is Correlated to Impaired Metabolism Due to Mitochondrial ROS Generation
Yong-Min Choi, Han‐Kyul Kim, Wooyoung Shim et al. · 2015 · PLoS ONE · 272 citations
The chemotherapeutic use of cisplatin is limited by its severe side effects. In this study, by conducting different omics data analyses, we demonstrated that cisplatin induces cell death in a proxi...
Reading Guide
Foundational Papers
Start with Özkök and Edelstein (2014, 678 citations) for AKI pathophysiology, then Zhou et al. (2013, 660 citations) for exosome renoprotection, and Peres and Cunha Júnior (2013, 259 citations) for molecular mechanisms.
Recent Advances
Study Holditch et al. (2019, 345 citations) for biomarkers/interventions, Fang et al. (2021, 340 citations) for natural products, and McSweeney et al. (2021, 320 citations) for genetic mitigations.
Core Methods
Core techniques: Mouse/rat cisplatin models for oxidative stress assays, exosome isolation from stem cells (Zhou et al., 2013), natural extract screening (Fang et al., 2021), autophagy flux measurement (Takahashi et al., 2012).
How PapersFlow Helps You Research Antioxidant Renoprotective Strategies Cisplatin
Discover & Search
Research Agent uses searchPapers('antioxidant renoprotective cisplatin nephrotoxicity') to find 250M+ OpenAlex papers, then citationGraph on Özkök and Edelstein (2014, 678 citations) reveals high-impact clusters, and findSimilarPapers uncovers exosome therapies like Zhou et al. (2013). exaSearch targets 'NRF2 inducers cisplatin AKI' for novel interventions.
Analyze & Verify
Analysis Agent applies readPaperContent to extract mechanisms from Volarević et al. (2019), then verifyResponse with CoVe chain-of-verification flags contradictions in antioxidant-tumor balance claims. runPythonAnalysis processes biomarker data from Holditch et al. (2019) via pandas for statistical trends, with GRADE grading for evidence strength on natural products (Fang et al., 2021).
Synthesize & Write
Synthesis Agent detects gaps in clinical translation of NRF2 inducers via contradiction flagging across McSweeney et al. (2021) and Fang et al. (2021), then Writing Agent uses latexEditText for protocol drafts, latexSyncCitations to integrate 10+ papers, and latexCompile for publication-ready reviews. exportMermaid visualizes oxidative stress pathways from Özkök and Edelstein (2014).
Use Cases
"Analyze dose-response curves of N-acetylcysteine in cisplatin mouse models from recent papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on extracted dose data from Holditch et al., 2019) → researcher gets plotted EC50 curves and statistical p-values.
"Draft LaTeX review on natural antioxidants for cisplatin nephrotoxicity"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Fang et al., 2021; Pan et al., 2008) + latexCompile → researcher gets compiled PDF with figures and 20 citations.
"Find code for simulating cisplatin oxidative stress models"
Research Agent → paperExtractUrls (Choi et al., 2015) → paperFindGithubRepo → githubRepoInspect → researcher gets runnable Python scripts for mitochondrial ROS modeling.
Automated Workflows
Deep Research workflow scans 50+ papers on cisplatin AKI via searchPapers → citationGraph → structured report with GRADE-scored interventions (Özkök and Edelstein, 2014). DeepScan's 7-step analysis with CoVe verifies mechanisms in Volarević et al. (2019), checkpointing biomarker claims. Theorizer generates hypotheses on NRF2-exosome synergies from Zhou et al. (2013) and McSweeney et al. (2021).
Frequently Asked Questions
What defines antioxidant renoprotective strategies for cisplatin?
Strategies use agents like N-acetylcysteine, amifostine, and NRF2 inducers to reduce renal oxidative stress and apoptosis from cisplatin, preserving kidney function (Özkök and Edelstein, 2014).
What are key methods in this subtopic?
Methods include preclinical mouse models testing exosomes (Zhou et al., 2013), natural products (Fang et al., 2021), and autophagy modulation (Takahashi et al., 2012) alongside biomarker-guided dosing.
What are the most cited papers?
Top papers: Özkök and Edelstein (2014, 678 citations) on pathophysiology; Zhou et al. (2013, 660 citations) on exosomes; Volarević et al. (2019, 405 citations) on mechanisms.
What open problems remain?
Challenges include tumor-protective effects of antioxidants, lack of AKI biomarkers, and clinical translation of natural products (Holditch et al., 2019; Fang et al., 2021).
Research Chemotherapy-induced organ toxicity mitigation with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Antioxidant Renoprotective Strategies Cisplatin with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers